Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence

NCT07473622 · tracked via the Priya Life Science UK tracker
Sponsor
Qufora A/S
Phase
Not applicable
Started
2026-10-09
Last updated
2026-10-30

Condition(s) studied

Faecal IncontinenceChronic Constipation

Investigational drug(s) / intervention(s)

Transanal irrigation

Transanal irrigation: Transanal irrigation by use of irrigation devices

Study summary

This clinical investigation is a post-market, exploratory, randomised, parallel, open-label investigation comparing two UKCA/CE-marked transanal irrigation products for the management of faecal incontinence and/or chronic constipation of heterogenous origin. The aim of this investigation is to assess outcomes in a real-world clinical setting, by following the typical clinical routine, with randomisation and more frequent visits/phone calls as the only difference from typical clinical procedure.

During 4-week training period, participants will trained by nurse specialists on how to use the device to which they were randomised to and will be instructed to irrigate once per day. For the remainder of the investigation, participants will be advised to continue irrigation once daily (or a minimum of 3 times a week). Participants will be followed up via phone call or in-person visit up to 52 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Faecal incontinence (FI), chronic constipation (CC) or co-existing FI/CC, all of heterogenous origin * Positive Rome IV criteria for functional constipation and/or positive Rome IV criteria for faecal incontinence * 18 years or older * Ability to understand written and spoken English (due to questionnaire validity) * Ability to understand and provide written, informed consent prior to any investigation-specific procedures Exclusion Criteria: * Prior use of transanal irrigation * Neurogenic bowel dysfunction * Low anterior resection syndrome (this group will be excluded due to the possibility of being randomised to a balloon catheter). * Previous rectal and/or anal surgery (except minor rectal or anal surgery such as haemorrhoid procedures, anal fissure surgery, drainage of a perianal/rectal abscess, or other rectal or anal surgeries deemed minor by the investigator) * Physical disability that affects the ability to independently use the irrigation device * Intermittent use of opioids inducing chronic constipation * Patulous anus * Participation in research conflicting with the current investigation * Physical or mental conditions affecting the ability to comply with the clinical investigation plan * Pregnancy or plans to become pregnant during the investigation period

Primary outcome measure(s)

  • Bowel Irrigation Questionnaire (BIQ) 4-point ordinal scale — Week 4, 10, 26, and 52
    Participant experience with device (0: strongly disagree, 4: strongly agree)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Southampton Southampton United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473622 on ClinicalTrials.gov ↗ ← All trials in the UK